The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Role of Aldosterone in Renal Vascular Injury in Stroke-Prone Hypertensive Rats
Abstract
Abstract —Stroke-prone spontaneously hypertensive rats (SHRSP) on 1% NaCl drinking solution and Stroke-Prone Rodent Diet develop severe hypertension and glomerular and vascular lesions characteristic of thrombotic microangiopathy seen in malignant nephrosclerosis. We recently reported that spironolactone, a mineralocorticoid receptor antagonist, markedly reduced proteinuria and malignant nephrosclerotic lesions in these animals. This observation, together with our previous findings that angiotensin-converting enzyme inhibitors prevent the development of vascular damage, suggests that mineralocorticoids, as part of the renin-angiotensin-aldosterone system, play a pathophysiological role in this model. In the present study, we examined whether chronic (2-week) infusion of aldosterone can reverse the renal vascular protective effects of captopril in SHRSP. SHRSP received vehicle (n=8); captopril alone (50 mg · kg −1 · d −1 , orally) (n=10); aldosterone infusion alone (40 μg · kg −1 · d −1 , SC) (n=7); or captopril and aldosterone at 20 (n=6) or 40 (n=7) μg · kg −1 · d −1 . Systolic blood pressure was markedly elevated in all groups. Vehicle- and aldosterone-infused SHRSP developed severe proteinuria and comparable degrees of renal injury (21±3% and 29±3%, respectively) manifested as thrombotic and proliferative lesions in the arterioles and glomeruli. Captopril treatment reduced plasma aldosterone levels concomitant with marked reductions in proteinuria and the absence of histologic lesions of malignant nephrosclerosis. Aldosterone substitution at 20 or 40 μg · kg −1 · d −1 in captopril-treated SHRSP resulted in the development of severe renal lesions (16±3% and 21±2%, respectively) and proteinuria comparable with that observed in SHRSP given either aldosterone or vehicle alone. These findings support a major role for aldosterone in the development of malignant nephrosclerosis in saline-drinking SHRSP, independent of the effects of blood pressure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hypertension : pathophysiology, diagnosis, and management
Laragh, J. H., & Brenner, B. M. (1995) · Raven Press eBooks · Cited by 1,932
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
Brilla, C. G., & Weber, K. T. (1992) · PubMed · Cited by 505
Mineralocorticoid Blockade Reduces Vascular Injury in Stroke-Prone Hypertensive Rats
Rocha, R., Chander, P. N., Khanna, K., Zuckerman, A., & Stier, C. T. (1998) · Hypertension · doi:10.1161/01.hyp.31.1.451 · Cited by 496
Self-citationRole of aldosterone in the remnant kidney model in the rat.
Greene, E. L., Kren, S., & Hostetter, T. H. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118867 · Cited by 479
Rise in plasma concentration of aldosterone during long-term angiotensin II suppression
STAESSEN, J., LIJNEN, P., FAGARD, R., VERSCHUEREN, L. J., & AMERY, A. (1981) · Journal of Endocrinology · doi:10.1677/joe.0.0910457 · Cited by 339
Regulation of Aldosterone Secretion
Quinn, S. J., & Williams, G. H. (1988) · Annual Review of Physiology · doi:10.1146/annurev.ph.50.030188.002205 · Cited by 313
Hemodynamic basis for glomerular injury in rats with desoxycorticosterone-salt hypertension.
Dworkin, L. D., Hostetter, T. H., Rennke, H. G., & Brenner, B. M. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111349 · Cited by 282
Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion
Sun, Y. (1997) · Cardiovascular Research · doi:10.1016/s0008-6363(97)00097-7 · Cited by 230
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states
Young, M., Head, G., & Funder, J. (1995) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1995.269.4.e657 · Cited by 228
Gavras, H., Brunner, H. R., Laragh, J. H., Vaughan, E. D., Koss, M., Cote, L. J., & Gavras, I. (1975) · Circulation Research · doi:10.1161/01.res.36.2.300 · Cited by 202
Cited by
Aldosterone induces a vascular inflammatory phenotype in the rat heart
Rocha, R., Rudolph, A. E., Frierdich, G. E., Nachowiak, D. A., Kekec, B. K., Blomme, E. A. G., McMahon, E. G., & Delyani, J. A. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.01096.2001 · Cited by 655
Self-citationAldosterone/salt induces renal inflammation and fibrosis in hypertensive rats
Blasi, E. R., Rocha, R., Rudolph, A. E., Blomme, E. A. G., Polly, M. L., & McMahon, E. G. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00929.x · Cited by 542
Self-citationAldosterone: A Mediator of Myocardial Necrosis and Renal Arteriopathy
Rocha, R. (2000) · Endocrinology · doi:10.1210/en.141.10.3871 · Cited by 475
Self-citationThe incidence and implications of aldosterone breakthrough
Bomback, A. S., & Klemmer, P. J. (2007) · Nature Clinical Practice Nephrology · doi:10.1038/ncpneph0575 · Cited by 420
Chen, D., Li, X., Song, Q., Hu, C., Su, F., Dai, J., Ye, Y., Huang, J., & Zhang, X. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.11122 · Cited by 398
Mehdi, U. F., Adams-Huet, B., Raskin, P., Vega, G. L., & Toto, R. D. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2009070737 · Cited by 388
Bianchi, S., Bigazzi, R., & Campese, V. M. (2006) · Kidney International · doi:10.1038/sj.ki.5001854 · Cited by 338
Aldosterone: effects on the kidney and cardiovascular system
Briet, M., & Schiffrin, E. L. (2010) · Nature Reviews Nephrology · doi:10.1038/nrneph.2010.30 · Cited by 337
Nishiyama, A., Yao, L., Nagai, Y., Miyata, K., Yoshizumi, M., Kagami, S., Kondo, S., Kiyomoto, H., Shokoji, T., Kimura, S., et al. (2004) · Hypertension · doi:10.1161/01.hyp.0000118519.66430.22 · Cited by 314
Effects of Aldosterone on the Vasculature
Schiffrin, E. L. (2006) · Hypertension · doi:10.1161/01.hyp.0000201443.63240.a7 · Cited by 303
Aldosterone in the development and progression of renal injury
Hollenberg, N. K. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00701.x · Cited by 273
The renin-angiotensin-aldosterone system, glucose metabolism and diabetes
Giacchetti, G., Sechi, L. A., Rilli, S., & Carey, R. M. (2005) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2005.02.003 · Cited by 267
The Pathophysiology of Aldosterone in the Cardiovascular System
ROCHA, R., & FUNDER, J. W. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04415.x · Cited by 261
Self-citationMineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis
Barrera-Chimal, J., Girerd, S., & Jaisser, F. (2019) · Kidney International · doi:10.1016/j.kint.2019.02.030 · Cited by 261
Bomback, A. S., Kshirsagar, A. V., Amamoo, M. A., & Klemmer, P. J. (2008) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2007.10.040 · Cited by 261
Review of aldosterone- and angiotensin II-induced target organ damage and prevention
Struthers, A. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.11.037 · Cited by 257
Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo
Brown, N. J., Nakamura, S., Ma, L., Nakamura, I., Donnert, E., Freeman, M., Vaughan, D. E., & Fogo, A. B. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00277.x · Cited by 255
Endothelin Antagonism on Aldosterone-Induced Oxidative Stress and Vascular Remodeling
Pu, Q., Neves, M. F., Virdis, A., Touyz, R. M., & Schiffrin, E. L. (2003) · Hypertension · doi:10.1161/01.hyp.0000078357.92682.ec · Cited by 255
Connell, J. M. C., MacKenzie, S. M., Freel, E. M., Fraser, R., & Davies, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0030 · Cited by 182
Mineralocorticoid Receptors, Salt-Sensitive Hypertension, and Metabolic Syndrome
Fujita, T. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.149062 · Cited by 130
Sullivan, J. C., Semprun-Prieto, L., Boesen, E. I., Pollock, D. M., & Pollock, J. S. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00429.2007 · Cited by 96
Angiotensin II Induces Skeletal Muscle Atrophy by Activating TFEB-Mediated MuRF1 Expression
Du Bois, P., Pablo Tortola, C., Lodka, D., Kny, M., Schmidt, F., Song, K., Schmidt, S., Bassel-Duby, R., Olson, E. N., & Fielitz, J. (2015) · Circulation Research · doi:10.1161/circresaha.114.305393 · Cited by 92
Aldosterone Blunts Tubuloglomerular Feedback by Activating Macula Densa Mineralocorticoid Receptors
Fu, Y., Hall, J. E., Lu, D., Lin, L., Manning, R. D., Cheng, L., Gomez-Sanchez, C. E., Juncos, L. A., & Liu, R. (2012) · Hypertension · doi:10.1161/hypertensionaha.111.173195 · Cited by 65
Selvaraj, J., Sathish, S., Mayilvanan, C., & Balasubramanian, K. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1452-2 · Cited by 47
Metadata
- Authors
- Rocha, R., Chander, P. N., Zuckerman, A., & Stier, C. T.
- Venue
- Hypertension
- Published
- 1999-01
- Volume
- 33
- Issue
- 1
- Pages
- 232-237
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2002087415
- Cited by
- 310
- References
- 22
- FWCI
- 8.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.